Apogee Therapeutics, Inc.
APGE
주식 순위
#2350
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
주가
$135.07
마지막 동기화: 2026-09-04
시가총액
$8.36B
변동 (1일)
0.00%
변동 (1년)
152.56%
국가
US
거래 Apogee Therapeutics, Inc. (APGE)
카테고리
Healthcare
Apogee Therapeutics, Inc. (APGE)의 주가 이력
최고 종가: $135.07 (2026-09-01 기준)
최저 종가: $20.79 (2023-07-01 기준)
최저 종가: $20.79 (2023-07-01 기준)
Apogee Therapeutics, Inc.의 주가 이력 (2023 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2026 (TTM) | 17.47% |
| 2025 | 60.85% |
| 2024 | 96.41% |
| 2023 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.77 | -3.82% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
